QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (12) Citing Articles via Google Scholar Google Scholar Articles by Larson, D. A. Articles by Berger, M. S. Search for Related Content PubMed PubMed Citation

Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme

Departments of Radiation Oncology (D.A.L., J.M.S., M.W.M., P.K.S., W.M.W.) and Neurological Surgery (D.A.L., S.M.C., K.R.L., M.W.M., M.D.P., M.K.N., M.S.B.), University of California San Francisco, San Francisco, CA 94143, USA

¹ Address correspondence to David A. Larson, Department of Radiation Oncology, University of California San Francisco, San Francisco, CA 94143 (larson{at}radonc17.ucsf.edu).

Abstract

This study reports the initial experience at the University of California San Francisco (UCSF) with tumor resection and permanent, low-activity iodine 125 (¹²⁵I) brachytherapy in patients with progressive or recurrent glioblastoma multiforme (GM) and compares these results to those of similar patients treated previously at UCSF with temporary brachytherapy without tumor resection. Thirtyeight patients with progressive or recurrent GM were treated at UCSF with repeat craniotomy, tumor resection, and permanent, low-activity ¹²⁵I brachytherapy between June 1997 and May 1998. Selection criteria were Karnofsky performance score 60, unifocal, contrast-enhancing, well-circumscribed progressive or recurrent GM that was judged to be completely resectable, and no evidence of leptomeningeal or subependymal spread. The median brachytherapy dose 5 mm exterior to the resection cavity was 300 Gy (range, 150-500 Gy). One patient was excluded from analysis. Median survival was 52 weeks from the date of brachytherapy. Age, Karnofsky performance score, and preimplant tumor volume were all statistically significant on univariate analyses. Multivariate analysis for survival showed only age to be significant. Median time to progression was 16 weeks. Both univariate and multivariate analysis of freedom from progression showed only preoperative tumor volume to be significant. Comparison to temporary brachytherapy patients showed no apparent difference in survival time. Chronic steroid requirements were low in patients with minimal postoperative residual tumor. We conclude that permanent ¹²⁵I brachytherapy for recurrent or progressive GM is well tolerated. Survival time was comparable to that of a similar group of patients treated with temporary brachytherapy.

This article has been cited by other articles:

				D. A. Reardon, M. R. Zalutsky, G. Akabani, R. E. Coleman, A. H. Friedman, J. E. Herndon II, R. E. McLendon, C. N. Pegram, J. A. Quinn, J. N. Rich, et al. A pilot study: 131I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost Neuro-oncol, April 1, 2008; 10(2): 182 - 189. [Abstract] [Full Text] [PDF]

				N. A. Butowski, P. K. Sneed, and S. M. Chang Diagnosis and Treatment of Recurrent High-Grade Astrocytoma J. Clin. Oncol., March 10, 2006; 24(8): 1273 - 1280. [Abstract] [Full Text] [PDF]

				D. A. Reardon, G. Akabani, R. E. Coleman, A. H. Friedman, H. S. Friedman, J. E. Herndon II, R. E. McLendon, C. N. Pegram, J. M. Provenzale, J. A. Quinn, et al. Salvage Radioimmunotherapy With Murine Iodine-131-Labeled Antitenascin Monoclonal Antibody 81C6 for Patients With Recurrent Primary and Metastatic Malignant Brain Tumors: Phase II Study Results J. Clin. Oncol., January 1, 2006; 24(1): 115 - 122. [Abstract] [Full Text] [PDF]